In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient Care
Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.
CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition
Venetoclax has given new hope and better options to a notoriously hard-to-treat patient group.
Anaplastic Thyroid Cancer: Hope Emerges Amid Widening Range of New Therapies
Though scientific advances have been encouraging in the thyroid cancer space, there is much more work to be done to figure out exactly how to tailor the right therapy, or combination of therapies, for individual patients.
Many Challenges, Opportunities for CAR T-Cell Therapies in Lymphoma
Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.
As CLL Approaches Expand, Sequencing Questions Arise
Doctors and patients who can stick with a regimen despite relatively minor adverse event will ultimately have more options later in the treatment journey, which could then lead to better long-term outcomes in chronic lymphocytic leukemia.
TAPUR Results Roll Out, Bringing Potential New paradigms Into Focus
When patients with locally advanced or metastatic soft tissue sarcoma do not respond to standard chemotherapy, they face a difficult situation.
Quest for Immune Checkpoint Inhibitor Biomarkers–a Long but Exciting Road
T-cell–targeted immunomodulators burst onto the scene a decade ago, and investigators turned their focus to immune checkpoints such as CTLA-4, PD-1, and PD-L1 to develop new cancer-fighting strategies.
Oncology Leaders Take Action to Curb Lack of Diversity in Clinical Trials
Most of the time, evidence of a cancer therapy’s success in clinical trials is reassuring. This time, it was not.
Thrombosis Risk in Patients With MPNs and COVID-19 Highest for Patients With Essential Thrombocythemia
Major thrombosis is a significant danger for patients with MPN who become infected with COVID-19, and antithrombotic prophylaxis does not appear to eliminate the risk.
SAMHD1 Expression Not Associated With Outcome in Mantle Cell Lymphoma With Cytarabine Combo Treatment
Expression or mutations in SAMHD1 does not appear to be linked with failure-free survival or complete remission rates in patients with mantle cell lymphoma who are treated with high-dose cytarabine-based chemotherapy.
ASXL1 Mutations Linked with Survival, Progression in Primary Myelofibrosis
A new meta-analysis confirms that ASXL1 mutations could be an important prognostic indicator in patients with myeloproliferative neoplasms.
MCL35 Assay Stratifies Risk in Patients With Mantle Cell Lymphoma
A new multi-analyte prognostic assay has demonstrated the potential to risk-stratifying patients with mantle cell lymphoma based on the particular molecular signature of an individual patient’s cancer, according to a new study.
Surveillance for Second Primary Malignancy Recommended in Select Patients With Myelofibrosis Treated With Ruxolitinib
Patients with myelofibrosis who receive ruxolitinib appear to face a higher risk of second primary malignancy; these risks are suggested to be even higher in men and patients with a history of arterial thrombosis and prolonged hydroxycarbamide exposure.
New Community-Setting Data Affirm Ibrutinib’s Efficacy in R/R MCL
New data show patients with mantle cell lymphoma who were treated with ibrutinib in a community setting had similar outcomes to patients given the Bruton’s tyrosine kinase inhibitor in a clinical trial setting, a retrospective study showed.
Task Force Recommends Active Surveillance for Many Low-Risk Papillary Thyroid Microcarcinoma Patients
Active surveillance can be a safe and appropriate management strategy for patients with T1aN0M0 low-risk papillary thyroid microcarcinoma, though the decision to use the strategy requires multidisciplinary teams and patient input, according to a new report.
R-CHOP Found Superior in Grade 3A, 1-2-3A Follicular Lymphoma
A new retrospective analysis has suggested that the R-CHOP chemotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone leads to superior outcomes compared to rituximab plus bendamustine in patients with grade 3A follicular lymphoma.
Real-World Data Support Use of Polatuzumab Vedotin for Heavily Pretreated Patients with R/R DLBCL
Patients with relapsed or refractory diffuse large B-cell lymphoma who have not found success in 2 or more lines of therapy face stiff odds, but new data suggest polatuzumab vedotin–based therapies may help improve outcomes.
Patients With DLBCL Can Be Treated Successfully Amid Pandemic, Study Finds
Despite concerns about treatment-related immunosuppression, a report out of Spain suggests SARS-CoV-2 precautions can offset risk for patients with diffuse large B-cell lymphoma.
Updated ALTERNATIVE Results Favor Dual HER2 Blockade in HER2+/HR+ Metastatic Breast Cancer
“Dual targeting of HER2-positive tumors with [trastuzumab] and [lapatinib] is beneﬁcial because of differing mechanisms of action and because of the well-characterized synergistic interaction between them in HER2 [breast cancer] models."
PET-Guided Therapy Improves Outcomes in Patients With Limited-Stage DLBCL
Use of interim positron emission tomography scans to direct patient care has established a new standard treatment approach for patients with limited-stage diffuse large B-cell lymphoma. These findings are from the Intergroup National Clinical Trials Network S1001 study.
Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer
Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.
New Analysis of Somatic Alterations Identifies Low-Risk Multiple Myeloma Subgroup
A new study has identified genomic factors that appear to correlate with a better risk profile and better progression-free survival among patients with multiple myeloma. The findings, though preliminary, could someday lead to better patient empowerment and stratification.
Phase 3 Study Confirms Benefit of Venetoclax/LDAC in Chemotherapy-Ineligible AML
A new randomized placebo-controlled study finds patients with acute myeloid leukemia who cannot undergo intensive chemotherapy have improved outcomes when given venetoclax in addition to low-dose cytarabine.
TP53, KMT2D Abnormalities Linked With Poor Prognosis in MCL
Patients receiving high-dose therapy for mantle cell lymphoma are at a higher risk of treatment failure if they have mutations in the TP53 or KMT2D genes, according to new research.
Blast Phase Not Stalled With Ruxolitinib Treatment in Myelofibrosis, Study Shows
A new analysis of nearly 600 patients with myelofibrosis found patients who take ruxolitinib progress to blast phase at approximately the same rates as those who are ruxolitinib-naïve.
Tumor Mutational Load Can Help Fine-Tune Prognoses in CLL
Patients with chronic lymphocytic leukemia face uncertain futures, as clinicians can have a difficult time predicting whether and when a patient will need treatment. New research suggests tumor mutational load could be a helpful prognostic tool.
TCbHP/T-DM1+P Sequence Shows Promise in HER2+ Primary Breast Cancer
A new phase II trial showed higher pathological complete response rates in patients with HER2-positive breast cancer who took docetaxel, carboplatin, trastuzumab, and pertuzumab followed by trastuzumab emtansine, and pertuzumab, versus those who took only the former therapy.
Community Oncologists Critical to Success of CAR T-cell Therapy in R/R Large B-Cell Lymphoma
Few options exist for patients with relapsed or refractory large B-cell lymphomas who have already undergone 2 rounds of systemic therapy. New research shows axicabtagene ciloleucel might be a strong option, but community oncologists must play a role in patient identification and post-treatment follow-up.
2 Clarke Drive Cranbury, NJ 08512